Давид Серван-Шрейбер - Антирак. Новый образ жизни

Мои друзья были так добры, что прочитали самые ранние версии книги и поделились своими комментариями со мной. Я максимально использовал их добрые советы. Благодарю Ги Сотея, Полин Гийер, Клаудию и Анну Сеник, Ранду Чахал, Паскаля Берти, Кристиана Регуби, Фрэнсис Ламберт, Кристофа Бегина. А также Дени Лаза, моего друга с тех пор, как нам стукнуло одиннадцать лет, моего названого брата и первого вегетарианца, которого я знал (и над которым так много потешался!).

Спасибо также Энн Шофилд-Ги, которая делилась со мной своими обширными познаниями в английском языке и своим пониманием того, что будет правильно в английском переводе.

Мой отец умер в то время, когда я писал эту книгу. Ему уже не прочитать ее. Но тем, что я исследую эти нехоженые пути, я обязан его поддержке. С самого детства он учил меня смотреть за рамки видимого и обращаться к тому, что способно восстановить силу. Я все еще ощущаю его присутствие во время утренней медитации, особенно в трудные моменты. Я уверен, что отец будет со мной, когда мне понадобятся силы для дальнейшего развития этих идей.

Давид Серван-Шрейбер, остров Ре

1. Harach, H. R., K. O. Franssila, and V. M. Wasenius, “Occult Papillary Carcinoma of the Thyroid: A ‘Normal’ Finding in Finland: A Systematic Autopsy Study,” Cancer 56 , no. 3 (1985): 531-38.

2. Black, W. C., and H. G. Welch, “Advances in Diagnostic Imaging and Overestimations of Disease Prevalence and the Benefits of Therapy,” New England Journal of Medicine 328, no. 17 (1993): 1237-43.

3. Stewart, B. W., and P. Kleihues, eds., World Cancer Report (Lyon, France: W.H.O. IARC Press, 2003).

4. Yatani, R., T. Shiraishi, K. Nakakuki, et al., “Trends in Frequency of Latent Prostate Carcinoma in Japan from 1965-1979 to 1982-1986,” Journal of the National Cancer Institute 80, no. 9 (1988): 683-87.

5. Stewart and Kleihues, World Cancer Report.

6. Sorensen, T. I. A., G. G. Nielsen, P. K. Andersen, et al., “Genetic and Environmental Influences on Premature Death in Adult Adoptees,” New England Journal of Medicine 318 (1988): 727-32.

7. Lichtenstein, P., N. V. Holm, P. K. Verkasalo, et al. “Environmental and Heritable Factors in the Causation of Cancer—Analyses of Cohorts of Twins from Sweden, Denmark, and Finland,” New England Journal of Medicine 343, no. 2 (2000): 78-85.

1. World Cancer Research Fund, Food, Nutrition and the Prevention of Cancer: A Global Perspective (London: World Cancer Research Fund and American Institute for Research on Cancer, 2007).

2. Institut National du Cancer, Nutrition et prevéntion des cancers: des connaissances scientifiques aux recommandations (Paris: Ministere de la Santé et des Sports, 2009).

3. Knoops, K. T. B., et al., “Mediterranean Diet, Lifestyle Factors, and 10-Year Mortality in Elderly European Men and Women—The HALE Project,” JAMA 292 (2004): 1433-39.

4. Khaw, K.-T., et al., “Combined Impact of Health Behaviours and Mortality in Men and Women: The EPIC-Norfolk Prospective Population Study,” PLoS Medicine 5, no. 1 (2008), e12.

1. Spiegel, D., “A 43-Year-Old Woman Coping with Cancer,” JAMA 282, no. 4 (1999): 371-78.

2. Van Baalen, D. C., M. J. deVries, and M. T. Gondrie, “Psycho-social Correlates of ‘Spontaneous’ Regression in Cancer,” monograph, Department of General Pathology, Medical Faculty, Erasmus University, Rotterdam, The Netherlands, 1987.

3. Lerner, M., oral communication, Smith Farm Retreat, 2001.

4. Ornish, D., G. Weidner, W. R. Fair, et al., “Intensive Lifestyle Changes May Affect the Progression of Prostate Cancer,” Journal of Urology 174, no. 3 (2005): 1065-69, discussion 9-70.

5. Ornish, D., M. J. Magbanua, G. Weidner, et al., “Changes in Prostate Gene Expression in Men Undergoing an Intensive Nutrition and Lifestyle Intervention,” Proceedings of the National Academy of Sciences 105 (on press): 8369-74.

6. Ghadirian, P., S. Narod, E. Fafard, M. Costa, A. Robidoux, and A. Nkondjock, “Breast Cancer Risk in Relation to the Joint Effect of BRCA Mutations and Diet Diversity,” Breast Cancer Research & Treatment (2009).

7. Fradet, V., I. Cheng, G. Casey, and J. S. Witte, “Dietary Omega-3 Fatty Acids, Cyclooxygenase-2 Genetic Variation, and Aggressive Prostate Cancer Risk,” Clinical Cancer Research 15 (2009): 2559-66.

8. King, M.-C., J. H. Marks, J. B. Mandell, New York Breast Cancer Study Group, “Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2,” Science 302 (2003): 643-46.

1. Yalom, I., Existential Psychotherapy (New York: Basic Books, 1977). Есть перевод: Ирвин Ялом, Экзистенциальная психотерапия. Перевод Т.С.Драбкиной, М.: "Класс", 1999 http://www.psylib.org.ua/books/yalom01/index.htm

2. Ibid.

1. Westcott, R., “Can Miracles Happen?” British Medical Journal 325, no. 7363 (2002): 553.

2. Everson, T. C., “Spontaneous Regression of Cancer,” Progress in Clinical Cancer (1967): 79-95.

3. Cole, W. H., “Efforts to Explain Spontaneous Regression of Cancer,” Journal of Surgical Oncology 17, no. 3 (1981): 201-9.

4. Challis, G. B., H. J. Stam, G. B. Challis, et al., “The Spontaneous Regression of Cancer: A Review of Cases from 1900 to 1987,” Acta Oncologica 29, no. 5 (1990): 545-50.

5. Bodey, B., B. Bodey, Jr., S. E. Siegel, et al., “The Spontaneous Regression of Neoplasms in Mammals: Possible Mechanisms and Their Application in Immunotherapy,” In Vivo 12, no. 1 (1998): 107-22.

6. Papac, R. J., “Spontaneous Regression of Cancer: Possible Mechanisms,” In Vivo 12, no. 6 (1998): 571-78.

7. Van Baalen, D. C., M. J. deVries, and M. T. Gondrie, “Psycho-social Correlates of ‘Spontaneous’ Regression in Cancer,” monograph, Department of General Pathology, Medical Faculty, Erasmus University, Rotterdam, The Netherlands, 1987.

8. Cui, Z., M. C. Willingham, M. A. Alexander-Miller, et al., “Spontaneous Regression of Advanced Cancer: Identification of a Unique Genetically Determined, Age-Dependent Trait in Mice,” Proceedings of the National Academy of Sciences of the United States of America 100 (2003): 6682-87.

9. Hicks, A. M., G. Riedlinger, M. C. Willingham, et al., “Transferable Anticancer Innate Immunity in Spontaneous Regression/Complete Resistance Mice ,” Proceedings of the National Academy of Sciences of the United States of America 103, no. 20 (2006): 7753-58.

10. Trapani, J. A., and M. J. Smyth, “Functional Significance of the Perforin/Granzyme Cell Death Pathway,” Nature Reviews Immunology 2 (2005): 735-47.

11. Voskoboinik, I., and J. A. Trapani, “Addressing the Mysteries of Perforin Function,” Immunology and Cell Biology 84 (2006): 66-71.

12. Whiteside, T., and R. B. Herberman, “Characteristics of Natural Killer Cells and Lymphocyte-Activated Killer Cells,” Immunology and Allergy Clinics of North America 10 (1990): 663-704.

13. Head, J. F., F. Wang, R. L. Elliott, et al., “Assessment of Immunologic Competence and Host Reactivity Against Tumor Antigens in Breast Cancer Patients: Prognostic Value and Rationale of Immunotherapy Development,” Annals of the New York Academy of Sciences 690 (1993): 340-42.

14. Levy, S. M., R. B. Herberman, M. Lippman, et al., “Immunological and Psychosocial Predictors of Disease Recurrence in Patients with Early-Stage Breast Cancer,” Behavioral Medicine 17, no. 2 (1991): 67-75.

15. Imai, K., S. Matsuyama, S. Miyake, et al., “Natural Cytotoxic Activity of Peripheral-Blood Lymphocytes and Cancer Incidence: An 11-Year Follow-Up Study of a General Population,” Lancet 356, no. 9244 (2000): 1795-99.

16. Schantz, S. P., B. W. Brown, E. Lira, et al., “Evidence for the Role of Natural Immunity in the Control of Metastatic Spread of Head and Neck Cancer,” Cancer Immunology, Immunotherapy 25, no. 2 (1987): 141-48.

17. Herberman, R. B., “Immunotherapy,” in Clinical Oncology, ed. R. J. Lenhard, R. Osteen, and T. Gansler (Atlanta, GA: American Cancer Society, 2001), 215-23.

18. MacKie, R. M., R. Reid, and B. Junor, “Fatal Melanoma Transferred in a Donated Kidney 16 Years after Melanoma Surgery,” New England Journal of Medicine 348, no. 6 (2003): 567-68.

19. Cui, Z., “The Winding Road to the Discovery of the SR/CR Mice,” Cancer Immunity 3 (2003): 14.

20. Koebel, C. M., Vermi, W., Swann, J. B., et al., “Adaptive Immunity Maintains Occult Cancer in an Equilibrium State,” Nature 159 (2008): 363-76.

21. Imai, Matsuyama, Miyake, et al., “Natural Cytotoxic Activity of Peripheral-Blood Lymphocytes and Cancer Incidence.”

22. Herberman, “Immunotherapy.”

23. Levy, S. M., R. B. Herberman, A. M. Maluish, et al., “Prognostic Risk Assessment in Primary Breast Cancer by Behavioral and Immunological Parameters,” Health Psychology 4, no. 2 (1985): 99-113.

24. Lutgendorf, S. K., A. K. Sood, B. Anderson, et al., “Social Support, Psychological Distress, and Natural Killer Cell Activity in Ovarian Cancer,” Journal of Clinical Oncology 23, no. 28 (2005): 7105-13.

25. Schantz, Brown, Lira, et al., “Evidence for the Role of Natural Immunity in the Control of Metastatic Spread of Head and Neck Cancer.”

26. Dvorak, H. F., “Tumors: Wounds That Do Not Heal: Similarities Between Tumor Stroma Generation and Wound Healing,” New England Journal of Medicine 315, no. 26 (1986): 1650-59.

27. Balkwill, F., and A. Mantovani, “Inflammation and Cancer: Back to Virchow?” Lancet 357, no. 9255 (2001): 539-45.

28. Peek, R. M., Jr., S. Mohla, and R. N. DuBois, “Inflammation in the Genesis and Perpetuation of Cancer: Summary and Recommendations from a National Cancer Institute-Sponsored Meeting,” Cancer Research 65, no. 19 (2005): 8583-86.

29. Huang, M., M. Stolina, S. Sharma, et al., “Non-Small Cell Lung Cancer Cyclooxygenase-2-Dependent Regulation of Cytokine Balance in Lymphocytes and Macrophages: Up-Regulation of Interleukin 10 and Down-Regulation of Interleukin 12 Production,” Cancer Research 58, no. 6 (1998): 1208-16.